Design, Development and Characterization of Self Micro Emulsifying Drug Delivery System (SMEDDS) of Nebivolol Hydrochloride for Solubility Enhancement

This investigation sought to devise and evaluate a self-micro emulsifying drug delivery system (SMEDDS) tailored for Nebivolol hydrochloride (NBL), a potent third-generation β-1 receptor antagonist crucial in hypertension management. Despite its therapeutic efficacy, NBL faces the challenge of low bioavailability, standing at a mere 12%. To overcome this limitation, our study aimed to develop an effective SMEDDS formulation to enhance the solubility of Nebivolol hydrochloride. We conducted extensive solubility studies on various components, including Cremophore-RH 40 (Cr-RH 40), Peceol, and Gelucire 50/13 (Gel 50/13), to determine the optimal composition for SMEDDS formulation. In our methodology, we conducted solubility studies to identify the most suitable combination of Cr-RH 40, Peceol, and Gel 50/13 for the SMEDDS formulation. Additionally, we performed emulsification efficiency studies to achieve optimal emulsification of the oily phase, evaluating different surfactant mixtures to select the most suitable liquid and solid surfactants. Subsequently, the resulting formulation underwent comprehensive characterization, including analysis of particle size, zeta potential, polydispersity index, and various techniques such as differential scanning calorimetry, Infrared spectroscopy, transmission electron microscopy, permeability studies, and stability assessments. Upon formulation, our Nebivolol hydrochloride-loaded SMEDDS exhibited significant enhancements compared to the pure drug. Characterization results revealed a favorable particle size distribution, appropriate zeta potential, and a low polydispersity index. Differential scanning calorimetry and Infrared spectroscopy confirmed the compatibility of components, while transmission electron microscopy provided visual insights into morphological characteristics. Permeability studies demonstrated improved solubility, highlighting the potential of the SMEDDS formulation in addressing Nebivolol hydrochloride's bioavailability challenges. Our discussion underscored the observed enhancements in solubility and formulation characteristics, attributing the efficacy of the Nebivolol hydrochloride-loaded SMEDDS to the optimized composition, surfactant mixtures, and emulsification efficiency. Comprehensive characterization validated the stability and compatibility of the SMEDDS, offering insights into its potential as a drug delivery system for Nebivolol hydrochloride. These positive outcomes set the stage for future research aimed at enhancing Nebivolol hydrochloride's therapeutic efficacy through advanced delivery systems. In conclusion, our study successfully developed and characterized a highly lipophilic drug, Nebivolol hydrochloride, within a SMEDDS. The formulation displayed improved solubility and promising characteristics, suggesting its potential in overcoming the bioavailability challenges associated with Nebivolol hydrochloride and opening avenues for further advancements in drug delivery strategies for this antihypertensive agent.